ChemoCentryx shareholders approve $3.7B merger with Amgen

Oct. 18, 2022 5:45 PM ETAmgen Inc. (AMGN)By: Jonathan Block, SA News Editor
  • ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company.
  • With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels.
  • NASDAQ said ChemoCentryx's anticipated last day of trading will be Oct. 19.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.